Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS ranibizumab 36-week refill-exchange regimen in neovascular age-related macular degeneration
2024-516924-32-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Oct 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in exudative macular degeneration, sponsored by Roche. Primary endpoint: Change from baseline BCVA averaged over Weeks 68 and 72. Planned start Oct 2025; status: authorised.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-516924-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516924-32-00.